Tacrolimus: Immunosuppression following liver and kidney transplant

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 3, 1996, Pages 135-141

  Clark, W ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TACROLIMUS;

CLINICAL TRIAL; DRUG COST; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; REVIEW;

EID: 0029745966     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb00012.x     Document Type: Review

References (19)

1. Peters DH, Fitton A, Plosker GL, Faulds D. (1993) Tacrolimus. A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs, 46(4), 746-794.
2. Mallick NP. (1995) Renal transplantation. Medicine International, 23, 156-157.
3. Starzl TE, Todo S, Tzakis AG, Gordon RD, Makowka L, Strebe A, Podesta L, Yanaga K, Concepcion W, Iwatsuki S. (1989) Liver transplantation: an unfinished product. Transplantation Proceedings, 21, 2197-2200.
4. Hooks M. (1994) Tacrolimus, a new immunosuppressant - a review of the literature. Annals of Pharmacotherapy, 28, 501-510.
5. Anon. Prograf Datasheet. Fujisawa, London, May 1995.
6. Fung JJ, Todo S, Tzakis A, Demetris A, Jain A, Abu-Elmagd K, Alessiani M, Starzl TE. (1992) Conversion of liver allograft recipients from cyclosporin to FK506 based immunosuppression: benefits and pitfalls. Transplantation Proceedings, 23, 14-21.
7. Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessioni M, Abu-Elmagd K, VanThiel DH, Starzl TE. (1992) Conversion of liver allograft recipients from cyclosporin to FK506 immunosuppressive therapy - a clinicopathologic study in 96 patients. Transplantation, 58, 1056-1062.
8. US Multicenter FK506 Study Group. (1993) Use of Prograf (FK506) as rescue therapy for refractory rejection after liver transplantation. Transplantation Proceedings, 25, 679-688.
9. Tzakis AG, Fung JJ, Todo S, Reyes J, Green M, Starzl TE. (1992) Use of FK506 in pediatric patients. Transplantation Proceedings, 23, 924-927.
10. Uemoto S, Tanaka K, Honda K, Tokunaga Y, Sono K, Katch H, Yamamoto E, Takada Y, Ozang K. (1993) Experience with FK506 in living - related liver transplantation. Transplantation, 55, 288-292.
11. European FK506 Multicenter Liver Study Group. (1994) Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet, 344, 423-428.
12. US Multicenter FK506 Liver Study Group. (1994) A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. New England Journal of Medicine, 331, 1110-1115.
13. McDiarmid SV, Busuttil RW, Ascher NL, Burdich J, D'Allessandro AM, Esquire C, Kalayoglu M, Klein AS, Marsh JW, Miller CM, Schwartz ME, Shaw BW, So SK. (1995) FK506 (tacrolimus) compared with cyclosporin for primary immunosuppression after paediatric liver transplantation. Transplantation, 56, 530-536.
14. Fung J. (1991) A randomised trial of primary liver transplantation under immunosuppression with FK506 vs. cyclosporin. Transplantation Proceedings, 23, 2977-2983.
15. Todo S, Fung JJ, Starzl TE, et al. (1994) Single-center experience with primary orthotopic liver transplantation with FK506 immunosuppression. Annals of Surgery, 220, 297-309.
16. Jordan ML, Shapiro R, Vivas CA, et al. (1993) FK506 salvage of renal allografts with ongoing rejection failing cyclosporin immunosuppression. Transplantation Proceedings, 25, 638-640.
17. Shapiro R, Jordan M, Scantlebury V, et al. (1991) FK506 in kidney transplantation. Transplantation Proceedings. 23, 3065-3067.
18. Schleibner S, Krauss M, Wagner K, Erhard J, Christiaans M, van Hooff J, Buist L, Maye D. (1995) FK506 versus cyclosporin in the prevention of renal allograft rejection - European Pilot Study: 6 week results. Transplantation International. 8, 86-90.
19. Fung JJ, Alessiani M, Abu-Elmagd K, et al. (1991) Adverse effects associated with the use of FK506. Transplantation Proceedings, 23, 3105-3108.